Daxor Corporation

Daxor Corporation Committed to advancing the field of healthcare by enabling optimal fluid management with blood volume analysis. (Nasdaq: $DXR)

Can we actually trust clinical "scores" for capillary leak?New data presented at the Society of Critical Care Medicine (...
03/26/2026

Can we actually trust clinical "scores" for capillary leak?

New data presented at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress suggests the answer is more complex than we thought.

The study, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured at the Research Snapshot Theater. The core takeaway? Traditional scoring methods often fail to catch the "hidden" reality of albumin escape.

Only BVA offers combined real-time albumin leak and direct volume measurement. This dual-metric approach brings precision medicine to critical care and heart failure, allowing clinicians to accurately diagnose and treat the underlying cause of fluid imbalance.

Learn more about the presentation in our latest press release:https://daxor.com/daxors-blood-volume-analysis-metric-validated-as-uniquely-accurate-versus-capillary-leak-indexes-in-new-clinical-data-presented-at-sccm-2026/

Nasdaq

03/05/2026



’s new BVA diagnostic technology empowers clinicians with sophisticated tools designed to bring clarity and deliver treatment plans grounded in precision.

Learn more about the potential of our BVA analyzer from our Chief Scientific Officer, Jonathan Feldschuh:

www.daxor.com



Disclaimers:
- The Daxor BVA™ and Volumex® are Rx Only and intended for use in adults by qualified, CLIA-certified professionals
- This information is for educational purposes only and is not a substitute for professional medical advice or a promotion of off-label use

03/03/2026

issues a corporate update in a Letter to Shareholders filed in its certified shareholder report from CEO & President, Michael Feldschuh.

Key updates include:

- 2025 marked a major inflection point, with net assets rising to $45.9M (+$10.1M YoY), NAV increasing to $9.07 per share, and operating revenue growing 45%. In January 2026, Daxor further strengthened its balance sheet with a $9M registered direct offering

- received FDA 510(k) clearance for its next-generation portable Blood Volume Analyzer, delivering results 3x faster in a compact, 7-pound system. Adoption expanded across multiple health systems and cardiology groups nationwide, supported by a dual model of on-site analyzers and 24-hour lab services

- New peer-reviewed studies reinforced the life-saving value of precise measurement in and . Daxor exited investment holdings and is transitioning regulatory reporting to align fully as a growth-focused medical diagnostics company, dedicating 100% of resources to Blood Volume Analysis commercialization

Read the full letter here: https://daxor.com/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-in-letter-to-shareholders-8/

Nasdaq

Why are "normal" lab results leaving Long COVID patients without answers? 🤔A new case study reveals that standard hemato...
02/20/2026

Why are "normal" lab results leaving Long COVID patients without answers? 🤔

A new case study reveals that standard hematocrit tests can mask serious underlying issues. While patient "Jenny" appeared healthy on paper, Blood Volume Analysis (BVA) unmasked a 18.2% total volume and 21.8% red cell deficit.

By moving from guesswork to precision, BVA identifies the objective volume phenotypes needed to provide targeted, effective treatment for dysautonomia and fatigue.

Read how BVA is uncovering some of the invisible drivers of Long COVID in this months : https://www.linkedin.com/posts/daxorcorporation_bvabrief-longcovid-dysautonomia-activity-7430685327515701248-iei6?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM

LVAD Outcomes Just Got Better!New data from Wellstar Health System presented at shows a perioperative strategy featuri...
10/31/2025

LVAD Outcomes Just Got Better!

New data from Wellstar Health System presented at shows a perioperative strategy featuring significantly reduces complications and boosts survival for patients:

1-Year Survival: Increased from 79.6% to 87.8%
Kidney Injury (RRT): Dropped from 34.1% to 10.6%
Readmissions: Down from 28.6% to 16.3%
Post-Operative Length of Stay: Decreased by 1.5 days

BVA is helping clinicians optimize care and improve long-term results!

Learn more: https://www.linkedin.com/posts/daxorcorporation_hfsa-cardiology-lvadcare-activity-7390070113082695680-rVAJ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM

🚀 Daxor is proud to debut our awaited new BVA diagnostic system at the MedAxiom - An ACC Company CV Transforum Fall '25 ...
10/15/2025

🚀 Daxor is proud to debut our awaited new BVA diagnostic system at the MedAxiom - An ACC Company CV Transforum Fall '25 in Austin (Oct. 16-18).

🤝 We are excited to be connecting with leaders in cardiovascular care to showcase how our new diagnostic is the catalyst to tackle key challenges like hospital readmissions and resource optimization.

🔗Read more: https://daxor.com/daxors-new-bva-technology-to-be-showcased-at-medaxiom-cv-transforum-fall-25/

Nasdaq


🏆 The Standard of Care Just Changed: Data from HFSA Validates BVA as Essential Diagnostic."Clinical findings provide und...
09/30/2025

🏆 The Standard of Care Just Changed: Data from HFSA Validates BVA as Essential Diagnostic.

"Clinical findings provide undeniable evidence that BVA is an essential diagnostic for improving care and reducing costs,” – John L. Jefferies, MD, MPH, MBA, CMO.

This definitive statement follows the debut of our FDA-cleared, next-generation BVA analyzer and the presentation of pivotal data:

✅ Banner UMC: Showed ZERO unplanned readmissions for patients guided by BVA.

✅ Wellstar Health: Demonstrated substantial cuts in AKI/RRT, readmissions, and length of stay for LVAD patients.

✅ Geisinger Medical Center: Showed BVA identifies a unique phenotype in cardiac amyloidosis, assisting clinicians with accurate diuretic dosing.

This substantial clinical validation positions Daxor to ensure BVA technology becomes widely accessible, making its benefits available to all patients.

Read more: https://daxor.com/daxor-unveils-new-fda-cleared-bva-analyzer-amid-strong-market-demand-and-pivotal-clinical-data-at-hfsa/

Nasdaq
Banner Health
Geisinger
Wellstar Health System


Address

107 Meco Lane
Oak Ridge, TN
37830

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Daxor Corporation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Daxor Corporation:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

Our Mission It is our goal to partner with hospitals and physicians to integrate direct blood volume measurement into standard clinical practice.

https://youtu.be/4a1dXHRfY6o

About Us Daxor Corporation is an innovative medical instrumentation and biotechnology company focused on blood volume analysis. We manufacture the BVA-100 Blood Volume Analyzer; the only rapid, clinically-available, FDA-cleared diagnostic to provide direct measurement of a patient’s blood volume in a broad range of medical conditions.

Transforming Healthcare Dozens of peer-reviewed studies have established the value of Daxor’s diagnostic, confirming that accurate blood volume analysis leads to better informed physicians, better treatment strategies, and improves patient outcomes and resource utilization.